Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial
Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial
复制标题
DOI：
10.1186/s13075-017-1484-9
复制
发表时间：
2018-01-16
影响因子：
4.9
通讯作者：
Marshall, Lisa
中科院分区：
文献类型：
--
作者：
Smolen, Josef S.;Szumski, Annette;Marshall, Lisa
背景：目的是分析中度活动性类风湿关节炎（RA）患者在接受全剂量依那西普加甲氨蝶呤诱导治疗后减少剂量依那西普或停用依那西普的缓解诱导和随后缓解丧失的预测特征。方法：基于28关节计数（DAS28）的患者疾病活动评分>3.2和
Background: The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction therapy followed by reduced-dose etanercept or etanercept withdrawal.Methods: Patients with Disease Activity Score based on 28-joint count (DAS28) >3.2 and